IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.

导出 LinkOut

翻译打印收藏纠错

作者： Marlene,Gyldmark ^[1] ; Kristian,Lampe ^[2] ; Jörg,Ruof ^[3] ; Johannes,Pöhlmann ^[4] ; Ansgar,Hebborn ^[5] ; Finn Børlum,Kristensen ^[6]

作者单位： MORSE - Health Technology Assessment Group, F. Hoffmann-La Roche, Pharmaceuticals Division, Global Pricing and Market Accessmarlene.gyldmark@roche.com. ^[1] Independent HTA expert. ^[2] r-connect GmbH. ^[3] Ossian Health Economics and Communications. ^[4] Global Market Access Policy,F. Hoffmann-La Roche. ^[5] Faculty of Health Sciences,University of Southern Denmark. ^[6]

关键词 Biomedical Biomedical technology Economics Healthcare sector Pharmaceutical Reference standards Technology assessment

主题词制药工业(Drug Industry);模型, 理论(Models, Theoretical);技术评估, 生物医学(Technology Assessment, Biomedical);技术转让(Technology Transfer)

DOI 10.1017/S0266462318000594

PMID 30334508

发布时间 2019-03-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交